Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Eli Lilly ( LLY 3.84%) and Novo Nordisk ( NVO 2.01%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the ...

This is partly thanks to Zepbound ... to become an important part of Eli Lilly's lineup. However, there are plenty of other reasons to invest in the stock. Lilly has outperformed the market ...

Here's where the company and its stock stand now ... heard of Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound. These are currently the dominant brand-name GLP ...